Innate Pharma

Innate Pharma

Innate Pharma was founded in 1999 in Marseille, France, by Hervé Brailly, Eric Vivier, and other academic researchers who believed in the therapeutic potential of natural killer (NK) cells. The company was built to bridge university immunology labs and commercial drug development, taking an unconventional route for a biotech by going public on Euronext Paris in 2006. This public listing makes its capital strategy distinct from typical asset managers: it funds R&D through a combination of equity raises, licensing deals, and milestone payments from large pharmaceutical partners. Innate Pharma develops antibody-based immunotherapies targeting both NK cells and tumor antigens. Its lead asset, monalizumab, is a checkpoint inhibitor partnered with AstraZeneca in a global deal that included a $800 million commercial launch milestone pool and $50 million initial payment in 2018. A second major collaboration with Sanofi, signed in 2016, brought in €400 million upfront to co-develop bispecific antibodies engaging NK cells. The firm's own pipeline includes lacutamab, a first-in-class anti-KIR3DL2 antibody for cutaneous T-cell lymphomas, and IPH6501, a next-generation NK cell engager. Clinical programs span haematological malignancies and solid tumors, with trials running across Europe and the United States. Innate Pharma operates a hybrid model: it retains wholly owned clinical-stage assets while monetizing earlier-stage platforms through Big Pharma alliances. The firm's financial disclosure shows approximately €62 million in cash and equivalents at year-end 2022, funded by a €75 million public offering and regular milestone receipts from AstraZeneca and Sanofi. Research operations are anchored in Marseille's Luminy science park, with a small clinical development team in the US. The structure operates with scientists running translational research, supported by a dealmaking front-office that has repeatedly secured top-tier pharmaceutical partnerships without dilutive, venture-style fundraising rounds. What structurally differentiates Innate Pharma is its dual posture as a publicly listed R&D company and an asset-origination engine for large pharmaceutical groups. Unlike a venture firm that syndicates risk across a portfolio, Innate concentrates scientific and financial resources into NK cell biology, creating a deep technological moat. The governance model separates an operational board from its founders on a supervisory board, maintaining academic links through its founding immunologists while Mondher Mahjoubi handles executive decision-making since his 2016 appointment as CEO.